Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or Amirah Al Idrus (email | Twitter), and we will feature it here at the end of each week.
Aegerion's embattled CEO Beer steps down |
|||||||||||||||||||
After a standoff with activist investors at Sarissa Capital, Marc Beer stepped down this week, ending his nearly 5-year run as Aegerion's ($AEGR) CEO. During his tenure, he saw the company go public and launch its first drug, but also landed in trouble with the FDA after getting a bit too bullish on CNBC last year. The move comes as the company's future is uncertain due to Sanofi ($SNY) and Regeneron's ($REGN) recent approval for cardiovascular therapy Praluent, which may imperil Aegerion's already-modest Juxtapid revenue. Along with Beer, chief operating officer Craig Fraser has resigned. Sandford Drexel Smith will lead the company on an interim basis while chairman David Scheer seeks a permanent chief executive. Story | Release
|